Objective: Fentanyl (FEN) is a potent, synthetic narcotic used as an anaesthetic and a pain reliever, but also illegally manufactured. For diversion purpose, it is being steadily modified to produce new analogous compounds and derivatives (FENS), categorised as novel psychoactive substances. While potential FEN abuse is already known, even in the absence of a clear lethal dosage, there is still a shortage of data on its derivatives.
| INTRODUCTION
Fentanyl is a high-potency synthetic narcotic, also termed "synthetic heroin" (EMCDDA, 2012) . Several FEN derivatives (initially sufentanil, alfentanil, remifentanil, carfentanil, and, more recently, acetylfentanyl, isobutyrylfentanyl, furanylfentanyl, methylacetylfentanyl,  acrylfentanyl, 2-fluorofentanyl, fluoroacetylfentanyl, ocfentantanyl, and many others) are illegally manufactured (Henderson, 1988; Higashikawa & Suzuki, 2008; Mounteney, Giraudon, Denissov, & Griffiths, 2015; Vardanyan & Hruby, 2014) .
Like other novel psychoactive substances (NPS), FEN and its derivatives (fentanyles or FENS) originate from two major sources.
FEN is commonly employed in general anaesthesia, surgery premedication, and chronic pain management, because of uniquely advantageous pharmacodynamic properties, including quick and short action, few cardiovascular risks, and low histamine release (EMCDDA, 2012; Kuhlman, McCaulley, Valouch, & Behonick, 2003) .
The use of FEN as a therapeutic drug is declining slightly (Peterson et al., 2016) , contrarily to other anaesthetic pain relievers, and no medical uses are recognized for most of its derivatives. In a framework of epidemic opioid misuse and abuse (Compton & Volkow, 2006; Jones, 2016 ; U.S. Department of Health and Human Services, 2015) , FEN and its congeners, also known as "white heroin," "Perc-O-Pops," "Chiclets" (Kuhlman et al., 2003) , follow a similar, if not steeper, trend (Peterson et al., 2016; Rudd, Aleshire, Zibbell, & Gladden, 2016) .
In the United States, between 2013 and 2014, the age-adjusted rate of deaths involving synthetic opioids increased by 80% (Rudd et al., 2016) and by 250% among younger people (Peterson et al., 2016) .
Between April and November 2015, the Swedish STRIDA project revealed 14 analytically confirmed intoxications involving fentanyl derivatives (Helander, Bäckberg, & Beck, 2016) . The upsurge in fentanyl-related deaths could be related to several factors. The high potency of the compound and the possibility of illegally manufacturing several doses from a small amount of pure substance could explain the high risk of overdose. It is estimated that 2.5 g of pure 3-methylfentanyl (3MF) is enough to produce 10,000 doses (EMCDDA, 2014; Mounteney et al., 2015) . The growing number of online pharmacies and Internet sales contributes to the easiness of NPS use and abuse (Mounteney et al., 2015) . Despite this boost in FEN diversion, there has been little investigation into FEN-related deaths. This paper reviews and discusses FENS-related deaths, aiming to provide a global medico-legal and toxicological assessment of the phenomenon.
tion," and "misuse" were used. References were examined and crosschecked. PubMed suggestions were considered and included when they agreed with the criteria. Only deaths were considered; patients rushed to the emergency department and then declared dead were also included. Analysis was not extended to articles written before 1990.
Within the context of a constant evolution of novel molecules, new deaths involving FENS are reported almost every day. Therefore, the bias of unconsidered cases was taken for granted.
Both overdose and drug poisoning were considered, even in the case of clear analgesic purpose, and categorized as FEN or mixed drug (MD) toxicity. MD included also ethanol as a source of intoxication.
When evidence was available, suicides were highlighted, both in natural and unnatural deaths.
With regard to concentrations of the compounds (and of the main metabolites, if available), only blood and, when stated, liver, urine, and stomach content concentrations were reported. Main findings were elaborated to allow easier interpretation. When possible, data from systematic reviews and official documents were also employed. The literature review was not restricted to English language nor to abstract-only papers, but detailed reports and clear results indicating papers were preferred.
| RESULTS
Results are shown in Table 1 .
With regard to pathological findings, visceral and especially pulmonary oedema and congestion were invariably described, with just a few exceptions (Juebner, Fietzke, Beike, Rothschild, & Bender, 2014) . Cardiac and liver abnormalities (organomegaly, fatty infiltration, or fibrosis) and gastric content aspiration were reported.
No difference between FENS, particularly 3-methyl fentanyl (3MF), acetyl fentanyl (ACFEN), butyr fentanyl (BFEN) and ocfentanil (INN), FEN and opioids were noted in postmortem examinations (Coopman, Cordonnier, De Leeuw, & Cirimele, 2016; Cunningham, Haikal, & Kraner, 2016; Dussy et al., 2016; Takase, Koizumi, Fujimoto, Yanai, & Fujimiya, 2016) . The only exception was a nonfatal case of butyrfentanyl intoxication, where widespread alveolar haemorrhage was found (excluded from our tab; Cole, Dunbar, McIntire, Regelmann, & Slusher, 2015) .
Pathological findings were not listed in the only furanyl fentanyl (FuF)-related case of death identified (Mohr et al., 2016 ).
It was not always possible to retrace the FENS administration route in all the cases analysed. The earliest articles described an intravenous (IV) use of FEN (Chaturvedi, Rao, & Baird, 1990; Henderson, 1991; Kronstrand, Druid, Holmgren, & Rajs, 1997; Levine, Goodin, & Caplan, 1990) , while more recent studies showed a prevalence of patch application for therapeutic or recreational purposes (Martin, Woodall Palamalai et al., 2013) . IV administration involved mostly men, aged 22 to 54 (Kronstrand et al., 1997; Kuhlman et al., 2003; Martin et al., 2006) , while patch users covered a wider age range (Gill, Lin, & Nelson, 2013; Martin et al., 2006) , with users older than 75-80 (Coopman, Cordonnier, Pien, & Van Varenbergh, 2007; Edinboro et al., 1997; Gill et al., 2013; Martin et al., 2006) .
In pain management, accidental or suicidal death can occur as a consequence of multiple patch application (Anderson & Muto, 2000; Edinboro et al., 1997; Martin et al., 2006) . When not directly prescribed, patches could be obtained from relatives (Flannagan, Butts, & Anderson, 1996; Thomas, Winecker, & Pestaner, 2008; Wiesbrock, Rochholz, Franzelius, Schwark, & Grellner, 2008) . The number of patches applied ranged from 34 (Juebner et al., 2014) , to just one lethal one (Anderson & Muto, 2000; Jumbelic, 2010; Kuhlman et al., 2003) .
Application to atypical areas, for example, bruised skin (Bakovic, Nestic, & Mayer, 2015) or oral cavities (Hull, Juhascik, Mazur, Flomenbaum, & Behonick, 2007; Kramer & Tawney, 1998; Martin et al., 2006; Moore, Palmer, & Donovan, 2015) , as well as licking, chewing, swallowing, or injecting the contents of prescription FEN patches, all resulting in enhanced absorption and a quick high (Anderson & Muto, 2000; Kuhlman et al., 2003; Thomas et al., 2008; Palamalai et al., 2013) , were reported. The injection of liquid extracted from patches or obtained from gel matrix was also found (Juebner et al., 2014; Martin et al., 2006; Reeves & Ginifer, 2002; Schauer, Shand, & Reynolds, 2015) . ACFEN, (Cunningham et al., 2016; McIntyre, Trochta, Gary, Malamatos, & Lucas, 2015; Yonemitsu, Sasao, Mishima, Ohtsu, & Nishitani, 2016) , 3MF (Ojanperä et al., 2006) (Marquardt & Tharratt, 1994) ; though the number of inhalation-related deaths is still low (Palamalai et al., 2013 , Takase et al., 2016 Coopman et al., 2016) .
Cause of death was often declared to be unknown or unclear, revealing the difficulties in post-mortem diagnosis (Anderson & Muto, 2000; Gill et al., 2013; Martin et al., 2006; Woodall, Martin, & McLellan, 2008) .
As regards toxicological findings, it should be noted that many papers, and particularly the earliest one, do not state the site of blood collection, nor the time between death and autopsy (Chaturvedi et al., 1990; Edinboro et al., 1997; Henderson, 1991; Kramer & Tawney, 1998; Levine et al., 1990; Smialek, Levine, Chin, Wu, & Jenkins, 1994) .
In Anderson & Muto, >69 ng/g in liver accounted for FEN overdose, while therapeutic levels were less than a third in concentration (Anderson & Muto, 2000) . Indeed, Palamalai et al. (2013) indicated a clear distinction between therapeutic and fatal levels in liver. However, not all cases of death due to FEN toxicity showed similar results, and only a few studies considered the liver concentration.
Average concentrations in FEN-only toxicities ranged from 9 ng/ml (Kuhlman et al., 2003) to 30 ng/ml more recently (Lung & Lemos, 2014) .
Considering the administration routes, mean FEN blood concentration in six transdermal cases was 21 ng/ml, significantly higher than the injected FEN value in the same series (Kuhlman et al., 2003) . Otherwise, no difference in lethal concentrations was found between transdermal and injected FEN (4.0 and 3.0 ng/ml; Martin et al., 2006). The stated therapeutic level of FEN concentrations is 0.30-3.8 ng/ ml (Anderson & Muto, 2000) . Some authors measured a post-mortem concentration of 7 ng/ml in deaths that were clearly not FEN-related (Anderson & Muto, 2000; Kuhlman et al., 2003) . However, several cancer patients widely exceeded these concentrations (Edinboro et al., 1997; Anderson & Muto, 2000) . Other studies found that concentrations in natural deaths can be as high as 15-33 ng/ml, while 3 ng/ml could be fatal (Martin et al., 2006; Thompson et al., 2007) . FEN concentrations did not differ in therapeutic and recreational purposes (Martin et al., 2006; Thompson et al., 2007) , and the lethal dose is hard to define for FEN. Very low blood concentrations (0.5 ng/ml) were reported in a case of 3MF-toxicity (Ojanperä et al., 2006) .
With regard to the coassumption of other drugs, 25 ng/ml was proposed as a value to identify FEN-only caused deaths (Lung & Lemos, 2014) . However, almost the same concentrations were reported when single or multiple drugs were discovered by toxicological analysis (Martin et al., 2006) . No statistical difference was observed between 3MF-only toxicity and MD (multidrug) toxicity (Ojanperä, Gergov, Liiv, Riikoja, & Vuori, 2008) .
| Pathological findings
In vivo effects of FEN-derived drugs (euphoria, respiratory depression, drowsiness, respiratory depression, and so on) resemble those of narcotics (Skulska, Kała, & Parczewski, 2005; Nelson & Schwaner, 2009; Stogner, 2014; Lee et al., 2016; Mohr et al., 2016) . Not surprisingly, many FEN-related deaths are discovered and must therefore be considered in suspected cases of overdose, even if the routine toxicological test is negative (Martin et al., 1991; Kronstrand et al., 1997; Mohr et al., 2016; Dussy et al., 2016) .
There is a substantial overlap between FENS and opioids in the spectrum of pathological findings (Biedrzycki, Bevan, & Lucas, 2009 In mice, intestinal bleeding was also reported (Higashikawa & Suzuki, 2008) . Further analysis is required to investigate pathological findings, especially of new molecules like FuF.
| Administration routes
Different administration routes for FEN are available for hospitalized patients and outpatients, such as liquid for injections or patches.
Because FEN is a small and highly lipid soluble molecule, with a large distribution volume (60-300 L; Reeves & Ginifer, 2002) , transdermal use is widespread. This is in accordance with our results. Other medicines containing FEN, in the form of oral tablets, sublingual tablets, and solutions intended for infusion, are less common (Mounteney et al., 2015) . Although patches were developed as a safe system for constant delivery of the substance ( When multiple substances involved, the analysed substance was reported before concentrations. Other concentrations: l: liver; st: stomach; u: urine. Technique: ELISA: enzyme-linked immunosorbent assay; GCMS: gas chromatography mass spectrometry; GCMS-MS: gas chromatography tandem spectrometry; LCMS: liquid chromatography mass spectrometry; LCMS-MS: liquid chromatography tandem mass spectrometry; SIM: specific ion monitoring; UPLC-MS-MS Ultra-performance liquid chromatography tandem mass-spectrometry. Study type. CR: case report; ED: emergency department; retr: retrospective study; u: unclear/unspecified.
Fatalities could arise in physician-controlled settings and could be due to patients' negligence (e.g., forgetting to remove a patch or application to bruised skin; Bakovic et al., 2015) . However, several intentional misuse and abuse procedures are described: multiple or atypical site application, licking or chewing, volatilization and inhalation, smoking, swallowing (Edinboro et al., 1997; Kramer & Tawney, 1998; Kuhlman et al., 2003; Lilleng, Mehlum, Bachs, & Morild, 2004; Martin et al., 2006; Thomas et al., 2008) , extraction of liquid by Durogesic heating or cutting (Reeves & Ginifer, 2002; Tharp et al., 2004; Nelson & Schwaner, 2009 ). Other assumption methods, such as rectal insertion (Coon, Miller, Kaylor, & Jones-Spangle, 2005) , are not consistent with our review.
The preferred administration route for new compounds is intravenous injection (Ojanperä et al., 2008; CDC, 2013; Cunningham et al., 2016; Yonemitsu et al., 2016; McIntyre et al., 2016) . Given the narrow range between effective and lethal doses, this is a matter for concern.
| Unsolved toxicological problems
There is no consensus regarding the correct medico-legal evaluation of FENS-related death. The appropriate site of collection is still under debate, despite preference for peripheral collection. Vitreous humour could represent a good alternative but more research is necessary (Coopman et al., 2007) .
FEN blood concentrations are influenced by many factors, like specimen collection timing. Despite the relevance of this factor, latency between death and autopsy is often not declared. Taken together, these factors hardly enable a comparison of concentrations from one paper to another in order to tentatively define threshold levels.
The high variability of post-mortem FEN concentrations in FENonly toxicities (9 to 30 ng/ml) relies on the wide range of the lethal dose, which could depend, among other factors, on the tolerance developed and on the route of administration. Our results showed an overlap in blood levels between incidental findings of FEN (in deaths due to other causes) and FENS-related death (Martin et al., 2006; Thompson et al., 2007; Lung & Lemos, 2014) , as well as in cases of recreational and therapeutic use.
Understanding lethal concentrations of FENS is challenging, given the frequent coassumption of multiple drugs (Nelson & Schwaner, 2009; Martin et al., 2006) .
Determination of the cause of death, where FENS are employed, is based on several case-specific considerations. This is consistent with the large number of deaths due to uncertain or questionable causes (Anderson & Muto, 2000; Martin et al., 2006; Woodall et al., 2008) .
Past medical history and ante-mortem distribution, scene investigation, post-mortem examination, and toxicological results must all be carefully considered and interpreted case by case (Thompson et al., 2007; Nelson & Schwaner, 2009; Palmer, 2010 , Krinsky et al., 2011 .
| Potential for abuse and concern
New synthetic FENS represent a widespread and growing field for the illegal market. It is reasonable to assume that FENS were initially a substitute for heroin or other opioids (Kuhlman et al., 2003; Skulska et al., 2005) . Although it is difficult to classify the typical FEN user (Krinsky et al., 2011; Mounteney et al., 2015) , as all ages and genders are involved, our results support the assumption that middle-aged men are the most common intravenous users of FEN, the profile being similar to that of heroin users. The number of younger users of FENS, like 3MF, is rising, reflecting the situation among heroin users. (Henderson, 1988; Martin et al., 1991; Kronstrand et al., 1997; Ojanperä et al., 2008; Tharp et al., 2004; Peterson et al., 2016) .
FENS are frequently sold for heroin (Stogner, 2014; Peterson et al., 2016) so their popularity could be related to trends in heroin availability and purity. However, in the majority of ACFEN-related deaths, no heroin was found. Therefore, an independent pattern of abuse is considered for BFEN, ACFEN, and INN (Lozier et al., 2015; Poklis et al., 2016; Coopman et al., 2016) .
The high potency of the compounds and patches availability could explain the potential of FENS abuse (Marquardt & Tharratt, 1994) . Even used patches still retain 28-84% of the original FEN content (Marquardt & Tharratt, 1994; Lilleng et al., 2004; Tharp et al., 2004; Juebner et al., 2014 ) and a single patch could be fatal (Martin et al., 2006; Carson, Knight, Dudley, & Garg, 2010) . Moreover, consumers can modify the desired effect by changing the administration route.
Chewing patches allows faster absorption and raises the dose 10-fold (Liappas et al., 2004) . Changes in the swallowing time of FEN tablets or patches has an influence on the dose absorbed, which is highly variable in vivo and post-mortem (Woodall et al., 2008) .
The issue is significant also for liquid recovered from patches, as it is difficult to control and predict the amount injected (Lilleng et al., 2004 ). This can be fatal.
Finally, it should be noted that the therapeutic range of FENS is narrower than that of morphine, heroin, or FEN itself. This is of particular interest because FENS are being continuously developed, because it has become harder for users to obtain illegal drugs and other drugs have been banned (Henderson, 1988; Tamburro, Al-Hadidi, & Dragovic, 2016) . This is even more significant for 3-methylfentanyl, as a very low concentration was found in the only death reported (Ojanperä et al., 2006) , but also true for FuF or ACFEN (Higashikawa & Suzuki, 2008; Takase et al., 2016) .
| CONCLUSION
The increasing number of recently discovered fentanyl-related deaths highlights the need to review the data available on these NPS.
The results of our analysis reveal the harmful potential of FENS, together with a large number of different procedures and administration routes, all possibly lethal.
Histo-pathological elements, toxicodynamics, and toxicokinetics have been collected from literature, providing an overview that refers mostly to opiate intoxication. However, there is a considerable amount of variability among substances and, in light of the common negative results of routine toxicological tests, the chemical-analytical approach to detecting intoxication is challenging.
Countermeasures, which could range from prevention of illegal FENS production and distribution (growing due to a lack of specific regulations) to supervision by those who prescribe them, are needed.
Finally, valuable toxicological-forensic instruments are necessary in order to contain the distribution of FENS. 
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